Lung Cancer Therapeutics Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Cancer Cell Type (Non-small Cell Lung Cancer (NSCLC), Small Cell Lung Cancer (SCLC)), By Treatment (Chemotherapy, Radiation Therapy, Immunotherapy, Targeted Therapy, Other Treatments), By Region & Competition, 2020-2030F

Market Overview

Global Lung Cancer Therapeutics Market was valued at USD 25.43 billion in 2024 and is expected to reach USD 40.55 billion by 2030 with a CAGR of 9.62% during the forecast period. The global lung cancer therapeutics market is witnessing robust growth due to increasing awareness, early diagnosis, and advancements in targeted and immunotherapies. Lung cancer remains one of the most commonly diagnosed and deadliest forms of cancer worldwide, making effective treatment a high priority for healthcare systems. The rising prevalence of smoking, exposure to environmental pollutants, and aging populations are key drivers fueling demand for innovative treatment options. Non-small cell lung cancer is the most prevalent type and has seen the greatest therapeutic advancements, especially through targeted therapies that focus on genetic mutations. Immunotherapies are also gaining momentum, offering hope by helping the body’s immune system recognize and attack cancer cells more effectively. These treatment modalities are reshaping the market landscape and improving patient survival rates. For instance, The World Health Organization (WHO) recognizes tobacco as a significant health risk, causing over 8 million deaths each year, especially in low- and middle-income countries. WHO supports actions like smoke-free policies, advertising restrictions, and tax increases to curb tobacco use and encourage smoking cessation.

Key Market Drivers

Rising Incidence of Lung Cancer

The rising incidence of lung cancer is one of the most significant drivers propelling the global lung cancer therapeutics market. For instance, the growing prevalence of various cancer types, with lung cancer being one of the most common, has led to an increasing demand for lung cancer therapeutics. Rising incidences of lung cancer across all demographics and age groups contribute to this demand. The American Cancer Society (ACS) reports that approximately 13% of all new cancer diagnoses are lung cancers.  Lung cancer continues to be one of the most frequently diagnosed cancers worldwide and remains a leading cause of cancer-related deaths. This growing burden is closely linked to widespread tobacco use, which remains the most common risk factor, particularly in low- and middle-income countries where smoking rates are still high. The exposure to secondhand smoke, environmental pollutants, occupational carcinogens like asbestos, and increasing levels of urban air pollution have contributed to a broader and more diverse at-risk population.

The surge in lung cancer cases has heightened the need for timely diagnosis and effective treatment, prompting healthcare systems to invest more in therapeutics. This has led to significant market expansion, particularly in areas focused on advanced treatments like targeted therapies and immunotherapies. As more patients are diagnosed at earlier stages due to improved screening programs and public awareness initiatives, the opportunity for therapeutic intervention increases, further driving demand for innovative drug development.

The changing lifestyle patterns, increasing life expectancy, and a growing elderly population are contributing to a higher number of lung cancer diagnoses globally. The disease’s high mortality rate has also intensified efforts from pharmaceutical companies and research organizations to accelerate clinical trials and regulatory approvals for novel therapies. The global response to this growing health crisis is reflected in rising healthcare expenditures and policy reforms aimed at improving cancer care access.

Overall, the increasing incidence of lung cancer underscores the critical need for continued investment in therapeutic innovation and access. It not only highlights a major public health challenge but also creates strong momentum for the lung cancer therapeutics market as stakeholders prioritize more effective, personalized, and accessible treatments to address the growing patient population.

Advancements in Targeted Therapy and Immunotherapy

Advancements in immunotherapy and biologics have played a pivotal role in driving the global Lung Cancer Therapeutics Market. Immunotherapy, which harnesses the body's immune system to target and destroy cancer cells, has emerged as a game-changer in cancer treatment, offering a more targeted approach with fewer side effects than conventional therapies like chemotherapy. The growing success of immune checkpoint inhibitors, monoclonal antibodies, and cancer vaccines has significantly shifted the treatment landscape, providing new avenues for patients seeking alternative or complementary therapies to traditional methods. In April 2024, ImmunityBio revealed positive survival outcomes from the QUILT 3.055 trial, showing that ANKTIVA (nogapendekin alfa inbakicept-pmln), combined with checkpoint inhibitors, nearly doubled survival in second- and third-line NSCLC patients resistant to previous treatments. A meeting with the FDA is scheduled for June 2024 to discuss registration, while the company is also preparing for ANKTIVA's launch in NMIBC.

Biologics, including monoclonal antibodies and cytokine therapies, are designed to mimic or enhance natural biological processes to treat cancer. These therapies offer a more personalized approach by targeting specific molecules involved in cancer cell growth, which reduces damage to healthy tissues. The ability of biologics to address specific genetic mutations or immune system deficiencies has made them an attractive alternative to more invasive and generalized treatments. As a result, patients are increasingly turning to biologic treatments as a means to improve outcomes, particularly in cases where traditional therapies have limited effectiveness.

The rapid development of personalized cancer immunotherapy, tailored to the individual’s genetic makeup, has significantly fueled the growth of the Lung Cancer Therapeutics Market. The promise of these therapies to offer better efficacy, with a reduced risk of recurrence and fewer side effects, is encouraging patients and healthcare professionals alike to explore these alternatives. This trend has led to increased investment in research and development, with pharmaceutical companies racing to develop new immunotherapy treatments and biologics.

As immunotherapy and biologics continue to advance, they are expected to remain key drivers in the growth of the Lung Cancer Therapeutics Market. Their potential to offer more effective, less invasive, and targeted treatment options has attracted considerable attention, further validating their position as viable alternatives in cancer care.

Growing Geriatric Population

The growing geriatric population is a crucial factor driving the expansion of the global lung cancer therapeutics market. As life expectancy increases worldwide, the proportion of elderly individuals in the population is rising significantly. This demographic shift is particularly relevant to lung cancer, which is primarily a disease of aging. The risk of developing lung cancer increases markedly with age, as genetic mutations accumulate over time and the immune system’s ability to detect and eliminate abnormal cells declines. Consequently, older adults represent a substantial share of the lung cancer patient population, leading to a heightened demand for effective and tolerable treatment options.

This age-related vulnerability has important implications for therapeutic development and market growth. Elderly patients often present with multiple comorbidities and decreased organ function, making them less tolerant of aggressive treatments like traditional chemotherapy. As a result, there is growing interest in therapies that offer improved safety profiles, such as targeted treatments and immunotherapies. These newer modalities tend to be more precisely tailored and better tolerated, making them suitable for older patients who may not be eligible for conventional approaches.

The healthcare systems in many countries are prioritizing cancer care for the elderly, leading to increased screening, early diagnosis, and personalized treatment strategies. Pharmaceutical companies are also adapting clinical trial designs to include more elderly participants, ensuring that emerging therapies are appropriate for this key demographic segment.

The aging global population is therefore not only contributing to a larger pool of lung cancer patients but also influencing the types of treatments being developed and adopted. This trend is expected to continue in the coming years, making the geriatric segment a focal point for innovation and investment within the lung cancer therapeutics market. Addressing the specific needs of elderly patients is critical for enhancing care outcomes and driving sustained market growth.

Download Free Sample Report

Key Market Challenges

High Treatment Costs

High treatment costs are one of the most significant challenges facing the global lung cancer therapeutics market. While advancements in targeted therapies and immunotherapies have revolutionized the treatment landscape, these therapies come with high price tags. For instance, newer treatments that target specific genetic mutations, such as EGFR inhibitors or immune checkpoint inhibitors, can cost patients tens of thousands of dollars per year. This makes them financially inaccessible for a large portion of the global patient population, especially in low- and middle-income countries where healthcare systems may already be strained.

The high cost of these treatments is often a barrier for patients who do not have sufficient insurance coverage or financial support. In many regions, the lack of universal healthcare coverage means that out-of-pocket expenses for patients are significant. This situation can lead to delayed treatment or even treatment abandonment, resulting in poorer outcomes.For those who do access these therapies, long-term costs can be unsustainable, as many lung cancer therapies require continuous use.

Pharmaceutical companies argue that the high costs are necessary to recoup the considerable investments made in research, development, and clinical trials. However, the pricing of cancer therapies has sparked widespread debate, with calls for more affordable pricing models or reimbursement strategies to ensure equitable access to these life-saving treatments.

Ultimately, the high treatment costs create a divide between those who can afford cutting-edge therapies and those who cannot, limiting the global reach of these innovative treatments and hindering efforts to reduce lung cancer mortality rates worldwide.

Limited Access in Developing Regions

Limited access to lung cancer treatments in developing regions poses a significant challenge to the global lung cancer therapeutics market. In many low- and middle-income countries, healthcare infrastructure is underdeveloped, and access to advanced treatments like targeted therapies and immunotherapies is often restricted. These regions face numerous barriers, including insufficient healthcare funding, limited availability of specialized medical facilities, and a shortage of trained oncologists and healthcare professionals. As a result, many patients in these areas are unable to receive timely or appropriate treatments for lung cancer.

The high cost of novel therapies exacerbates the accessibility issue. In many developing countries, where healthcare systems struggle with budget constraints, the expensive nature of cutting-edge treatments means that only a small fraction of the population can afford them. This limits access even further, particularly in rural or underserved areas where there may be a lack of medical facilities altogether.

The availability of diagnostic tools is also a concern in these regions. Early detection is crucial for improving lung cancer survival rates, but in many developing countries, screening programs are limited or nonexistent. Without early detection, patients often seek medical attention only at later, more advanced stages of the disease, when treatment options are fewer and less effective.

These accessibility challenges not only hinder the effectiveness of lung cancer treatments but also contribute to the global disparity in cancer survival rates. To address this issue, there is a need for increased investment in healthcare infrastructure, affordable pricing models, and initiatives to raise awareness and improve access to early diagnosis and treatment in developing regions.

Key Market Trends

Shift Toward Personalized Medicine

The shift toward personalized medicine is one of the most significant trends in the global lung cancer therapeutics market, marking a transformative approach to treatment that aims to tailor therapies to individual patients based on their genetic, molecular, and environmental profiles. This paradigm shift is reshaping how lung cancer is diagnosed, treated, and managed, moving away from a one-size-fits-all approach to more targeted, effective, and less invasive therapies.

Personalized medicine in lung cancer relies heavily on identifying specific genetic mutations, biomarkers, and molecular characteristics of both the cancer cells and the patient. For example, targeted therapies are now developed to treat non-small cell lung cancer (NSCLC) based on mutations such as EGFR, ALK, ROS1, and BRAF. These therapies can directly target the molecular drivers of cancer growth, resulting in more effective treatments with fewer side effects than traditional chemotherapy. The success of targeted therapies in improving survival rates has demonstrated the value of personalized approaches and increased demand for genetic testing and biomarkers.

The growing field of immunotherapy, especially immune checkpoint inhibitors, has benefited from the personalized medicine trend. These therapies are often more effective in certain patients based on the expression of biomarkers like PD-L1. By identifying which patients are most likely to benefit from immunotherapy, healthcare providers can optimize treatment plans and avoid unnecessary therapies for those less likely to respond.

The expansion of personalized medicine has also spurred growth in companion diagnostics, which are essential for identifying the right patient populations for specific treatments. The availability of such diagnostics helps ensure that patients receive the most appropriate therapies based on their individual profiles, leading to better outcomes and a more efficient use of healthcare resources.

The shift toward personalized medicine is driving significant innovation in the lung cancer therapeutics market, making treatments more precise, effective, and patient-centered. As research advances, the integration of personalized approaches is expected to continue expanding, further improving survival rates and quality of life for lung cancer patients.

Combination Therapies

Combination therapies are becoming an increasingly important trend in the global lung cancer therapeutics market, as they offer enhanced treatment efficacy compared to single-agent therapies. This approach involves using two or more treatment modalities, such as chemotherapy, targeted therapy, and immunotherapy, in tandem to tackle the complexity of lung cancer from multiple angles. By combining therapies, healthcare providers aim to overcome resistance mechanisms, improve treatment responses, and prolong patient survival.

One of the key drivers behind the shift toward combination therapies is the recognition that lung cancer is a heterogeneous disease, meaning that different patients may respond differently to various treatment approaches. For example, combining chemotherapy with targeted therapies like EGFR inhibitors or ALK inhibitors can address the cancer’s genetic mutations while reducing the side effects typically associated with chemotherapy. Similarly, combining immunotherapy with chemotherapy or targeted therapies can help boost the body’s immune response to cancer cells while also addressing the tumor’s specific molecular profile.

Clinical trials are increasingly focused on exploring the efficacy of these combinations. Notably, immunotherapy combinations, such as using immune checkpoint inhibitors (e.g., PD-1/PD-L1 inhibitors) alongside chemotherapy, have shown promising results in improving survival rates, especially for patients with advanced-stage non-small cell lung cancer (NSCLC). As more combination therapies demonstrate their potential in clinical settings, the market is witnessing increased regulatory approvals and a growing number of combination treatment options available for lung cancer patients. Ultimately, combination therapies represent a powerful strategy for improving outcomes in lung cancer treatment, offering hope for patients with more advanced or resistant forms of the disease and significantly driving growth in the lung cancer therapeutics market.

Segmental Insights

Cancer Cell Type Insights

Based on Cancer cell type, Non-small cell lung cancer (NSCLC) dominated the global lung cancer therapeutics market, accounting for the majority of lung cancer cases. NSCLC represents approximately 85-90% of all lung cancer diagnoses, making it the most prevalent form of the disease. This dominance is due to the fact that NSCLC includes several subtypes, such as adenocarcinoma, squamous cell carcinoma, and large cell carcinoma, which are more common and develop more slowly than small cell lung cancer (SCLC). NSCLC is often diagnosed in its later stages, allowing for more advanced treatment options, including targeted therapies and immunotherapies, which have contributed to improved survival rates and better treatment outcomes. In contrast, SCLC, although aggressive and fast-growing, accounts for only about 10-15% of lung cancer cases. While treatment for SCLC involves chemotherapy and radiation, it is more difficult to treat due to its rapid progression and tendency to develop resistance to therapies, making NSCLC the dominant category in terms of market share.

Download Free Sample Report

Regional Insights

North America dominated the global lung cancer therapeutics market due to several key factors, including advanced healthcare infrastructure, high levels of healthcare spending, and strong regulatory frameworks that facilitate the approval of new treatments. The United States, in particular, has seen significant investment in cancer research and development, leading to rapid advancements in targeted therapies, immunotherapies, and combination treatments for lung cancer. North American countries have access to state-of-the-art diagnostic technologies, ensuring early detection and improved patient outcomes.

The region also benefits from a high prevalence of lung cancer, driven by smoking rates and aging populations, further fueling demand for lung cancer treatments. The presence of major pharmaceutical companies and research institutions in North America accelerates the development and commercialization of new therapies. Government initiatives, such as healthcare coverage and reimbursement schemes, also enhance access to innovative treatments, contributing to North America’s market dominance.

Recent Developments

• In April 2025, Akeso Inc. received approval from China's NMPA for Ivonescimab, a first-in-class bispecific antibody targeting PD-1 and VEGF. This approval enables Ivonescimab as a monotherapy for first-line treatment of advanced PD-L1-positive NSCLC patients without EGFR or ALK mutations, marking a significant treatment innovation.
• In August 2024, AstraZeneca’s Imfinzi was approved by the U.S. FDA for treating adult patients with resectable early-stage NSCLC, with no known EGFR mutations or ALK rearrangements. It is an immunotherapy combined with chemotherapy, offering a new option for patients with early-stage lung cancer who require a comprehensive treatment approach.
• In October 2024, Novocure’s Optune Lua, approved by the FDA, is a wearable device delivering Tumor Treating Fields (TTFields) for metastatic NSCLC patients whose cancer has progressed after platinum-based chemotherapy. This innovative therapy uses alternating electric fields to disrupt cancer cell division and promote tumor cell death, expanding treatment options.
• In May 2024, Pfizer announced long-term results from the phase 3 CROWN trial, showing LORBRENA significantly reduced disease progression in ALK-positive advanced NSCLC patients after 5 years of median follow-up. LORBRENA demonstrated an 81% reduction in progression rates compared to XALKORI, offering sustained clinical benefits for ALK-positive NSCLC patients.
• In March 2023, Roche’s VENTANA PD-L1 (SP263) Assay was approved as a companion diagnostic for NSCLC patients, identifying those suitable for immunotherapy. This diagnostic tool aims to increase patient access to immunotherapy options, ensuring targeted treatment for individuals with PD-L1 expression, thereby optimizing therapeutic outcomes.

Key Market Players

• AstraZeneca Plc
• Boehringer Ingelheim International GmbH.
• Bristol-Myers Squibb Company
• Eli Lilly and Company
• F. Hoffmann-La Roche Ltd.
• Merck & Co
• Pfizer Inc.
• Allergan Inc.
• Teva Pharmaceutical Industries Ltd.
• Abbvie, Inc.

Report Scope:

In this report, the Global Lung Cancer Therapeutics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

• Lung Cancer Therapeutics Market, By Cancer Cell Type:

o   Non-small Cell Lung Cancer (NSCLC)

o   Small Cell Lung Cancer (SCLC)

• Lung Cancer Therapeutics Market, By Treatment:

o   Chemotherapy

o   Radiation Therapy

o   Immunotherapy

o   Targeted Therapy

o   Other Treatments

• Lung Cancer Therapeutics Market, By Region:

o   North America

§  United States

§  Canada

§  Mexico

o   Europe

§  France

§  United Kingdom

§  Italy

§  Germany

§  Spain

o   Asia-Pacific

§  China

§  India

§  Japan

§  Australia

§  South Korea

o   South America

§  Brazil

§  Argentina

§  Colombia

o   Middle East & Africa

§  South Africa

§  Saudi Arabia

§  UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Lung Cancer Therapeutics Market.

Available Customizations:

Global Lung Cancer Therapeutics Market report with the given market data, TechSci Research, offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).